Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Saved in:
| Title: | Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. |
|---|---|
| Authors: | Dai MS; Department of Hematology-Oncology, Tri-Service General Hospital, Taipei, Taiwan., Feng YH; Department of Hematology-Oncology, Chi Mei Medical Center-Yongkang Branch, Tainan, Taiwan., Chen SW; Department of Hematology-Oncology, Chi Mei Medical Center-LiouYing Branch, Tainan, Taiwan., Masuda N; Department of Surgery and Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan., Yau T; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong., Chen ST; Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan., Lu YS; Division of Medical Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Yap YS; Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Ang PCS; Department of Medical Oncology, OncoCare Cancer Centre, Singapore, Singapore., Chu SC; Department of Hematology-Oncology, Hualien Tzu Chi Hospital, Hualien, Taiwan., Kwong A; Department of Surgery, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong., Lee KS; Center for Breast Cancer, National Cancer Center, Goyang-si, South Korea., Ow S; Department of Haematology and Oncology, National University Cancer Institute, Singapore, Singapore., Kim SB; Department of Oncology, Asan Medical Center, Seoul, South Korea., Lin J; Department of Hematology-Oncology, Mackay Memorial Hospital, Taipei, Taiwan., Chung HC; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Ngan R; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong., Kok VC; Division of Medical Oncology, Kuang Tien General Hospital Cancer Center, Taichung, Taiwan., Rau KM; Department of Hematology-Oncology, E-Da Cancer Hospital, Kaohsiung, Taiwan., Sangai T; Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan., Ng TY; Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong., Tseng LM; Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan., Bryce R; Puma Biotechnology Inc., Los Angeles, USA., Bebchuk J; Department of Biostatistics, Puma Biotechnology Inc., Los Angeles, USA., Chen MC; Clinical Development and Medical Affairs, CANbridge Pharmaceuticals Inc., Taipei, Taiwan., Hou MF; Division of Breast Oncology and Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital, No.100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. mifeho@kmu.edu.tw. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Oct; Vol. 189 (3), pp. 665-676. Date of Electronic Publication: 2021 Sep 23. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34553296 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Dai+MS%22">Dai MS</searchLink>; Department of Hematology-Oncology, Tri-Service General Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Feng+YH%22">Feng YH</searchLink>; Department of Hematology-Oncology, Chi Mei Medical Center-Yongkang Branch, Tainan, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chen+SW%22">Chen SW</searchLink>; Department of Hematology-Oncology, Chi Mei Medical Center-LiouYing Branch, Tainan, Taiwan.<br /><searchLink fieldCode="AU" term="%22Masuda+N%22">Masuda N</searchLink>; Department of Surgery and Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Yau+T%22">Yau T</searchLink>; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.<br /><searchLink fieldCode="AU" term="%22Chen+ST%22">Chen ST</searchLink>; Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lu+YS%22">Lu YS</searchLink>; Division of Medical Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Yap+YS%22">Yap YS</searchLink>; Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Ang+PCS%22">Ang PCS</searchLink>; Department of Medical Oncology, OncoCare Cancer Centre, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Chu+SC%22">Chu SC</searchLink>; Department of Hematology-Oncology, Hualien Tzu Chi Hospital, Hualien, Taiwan.<br /><searchLink fieldCode="AU" term="%22Kwong+A%22">Kwong A</searchLink>; Department of Surgery, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong.<br /><searchLink fieldCode="AU" term="%22Lee+KS%22">Lee KS</searchLink>; Center for Breast Cancer, National Cancer Center, Goyang-si, South Korea.<br /><searchLink fieldCode="AU" term="%22Ow+S%22">Ow S</searchLink>; Department of Haematology and Oncology, National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Kim+SB%22">Kim SB</searchLink>; Department of Oncology, Asan Medical Center, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Lin+J%22">Lin J</searchLink>; Department of Hematology-Oncology, Mackay Memorial Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chung+HC%22">Chung HC</searchLink>; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Ngan+R%22">Ngan R</searchLink>; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong.<br /><searchLink fieldCode="AU" term="%22Kok+VC%22">Kok VC</searchLink>; Division of Medical Oncology, Kuang Tien General Hospital Cancer Center, Taichung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Rau+KM%22">Rau KM</searchLink>; Department of Hematology-Oncology, E-Da Cancer Hospital, Kaohsiung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Sangai+T%22">Sangai T</searchLink>; Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Ng+TY%22">Ng TY</searchLink>; Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong.<br /><searchLink fieldCode="AU" term="%22Tseng+LM%22">Tseng LM</searchLink>; Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Bryce+R%22">Bryce R</searchLink>; Puma Biotechnology Inc., Los Angeles, USA.<br /><searchLink fieldCode="AU" term="%22Bebchuk+J%22">Bebchuk J</searchLink>; Department of Biostatistics, Puma Biotechnology Inc., Los Angeles, USA.<br /><searchLink fieldCode="AU" term="%22Chen+MC%22">Chen MC</searchLink>; Clinical Development and Medical Affairs, CANbridge Pharmaceuticals Inc., Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Hou+MF%22">Hou MF</searchLink>; Division of Breast Oncology and Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital, No.100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. mifeho@kmu.edu.tw. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2021 Oct; Vol. 189 (3), pp. 665-676. <i>Date of Electronic Publication: </i>2021 Sep 23. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34553296 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10549-021-06313-5 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 665 Titles: – TitleFull: Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Dai MS – PersonEntity: Name: NameFull: Feng YH – PersonEntity: Name: NameFull: Chen SW – PersonEntity: Name: NameFull: Masuda N – PersonEntity: Name: NameFull: Yau T – PersonEntity: Name: NameFull: Chen ST – PersonEntity: Name: NameFull: Lu YS – PersonEntity: Name: NameFull: Yap YS – PersonEntity: Name: NameFull: Ang PCS – PersonEntity: Name: NameFull: Chu SC – PersonEntity: Name: NameFull: Kwong A – PersonEntity: Name: NameFull: Lee KS – PersonEntity: Name: NameFull: Ow S – PersonEntity: Name: NameFull: Kim SB – PersonEntity: Name: NameFull: Lin J – PersonEntity: Name: NameFull: Chung HC – PersonEntity: Name: NameFull: Ngan R – PersonEntity: Name: NameFull: Kok VC – PersonEntity: Name: NameFull: Rau KM – PersonEntity: Name: NameFull: Sangai T – PersonEntity: Name: NameFull: Ng TY – PersonEntity: Name: NameFull: Tseng LM – PersonEntity: Name: NameFull: Bryce R – PersonEntity: Name: NameFull: Bebchuk J – PersonEntity: Name: NameFull: Chen MC – PersonEntity: Name: NameFull: Hou MF IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2021 Oct Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1573-7217 Numbering: – Type: volume Value: 189 – Type: issue Value: 3 Titles: – TitleFull: Breast cancer research and treatment Type: main |
| ResultId | 1 |
